Managed Account Advisors’s Puma Biotechnology PBYI Stock Holding History

Managed Account Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$523K	Sell	4,477 -23,387	-84%	-$4.24M	﹤0.01%	2293
2015 Q1	$6.58M	Buy	27,864 +2,658	+11%	+$568K	0.01%	1293
2014 Q4	$4.77M	Buy	25,206 +117	+0.5%	+$26K	﹤0.01%	1427
2014 Q3	$5.99M	Sell	25,089 -26,990	-52%	-$5.54M	0.01%	1291
2014 Q2	$3.44M	Buy	52,079 +12,320	+31%	+$876K	﹤0.01%	1551
2014 Q1	$4.14M	Buy	39,759 +20,994	+112%	+$2.47M	0.01%	1415
2013 Q4	$1.94M	Buy	18,765 +2,161	+13%	+$127K	﹤0.01%	1730
2013 Q3	$891K	Buy	16,604 +15,600	+1,554%	+$841K	﹤0.01%	1911
2013 Q2	$45K	Buy	+1,004	New	+$35.4K	﹤0.01%	2288

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Managed Account Advisors's PBYI Position: Q2 2015 in Review

Managed Account Advisors reduced its Puma Biotechnology (PBYI) stake by 84% in Q2 2015, selling an estimated $4.24M and leaving 4,477 shares worth $523K. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Managed Account Advisors first reported a position in PBYI in Q2 2013 and has held it in 9 quarters since. The position peaked at $6.58M in Q1 2015. 198 funds tracked by Wall St. Rank hold PBYI as of Q2 2015.

Managed Account Advisors held 4,477 shares of Puma Biotechnology worth $523K as of Q2 2015.
Managed Account Advisors sold 23,387 Puma Biotechnology shares in Q2 2015, an estimated $4.24M.
Puma Biotechnology made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2293 holding.
Managed Account Advisors first reported a position in Puma Biotechnology in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's Puma Biotechnology position peaked at $6.58M in Q1 2015.
198 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.